- Home
- AFJK vs ASMB Comparison
AFJK vs ASMB Comparison
Compare AFJK & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFJK
- ASMB
- Stock Information
- Founded
- AFJK 2023
- ASMB 2005
- Country
- AFJK United States
- ASMB United States
- Employees
- AFJK N/A
- ASMB N/A
- Industry
- AFJK
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- AFJK
- ASMB Health Care
- Exchange
- AFJK NYSE
- ASMB Nasdaq
- Market Cap
- AFJK 95.5M
- ASMB 106.5M
- IPO Year
- AFJK 2023
- ASMB 2010
- Fundamental
- Price
- AFJK $10.60
- ASMB $16.75
- Analyst Decision
- AFJK
- ASMB Buy
- Analyst Count
- AFJK 0
- ASMB 2
- Target Price
- AFJK N/A
- ASMB $35.00
- AVG Volume (30 Days)
- AFJK 5.9K
- ASMB 24.2K
- Earning Date
- AFJK 01-01-0001
- ASMB 11-07-2024
- Dividend Yield
- AFJK N/A
- ASMB N/A
- EPS Growth
- AFJK N/A
- ASMB N/A
- EPS
- AFJK 0.27
- ASMB N/A
- Revenue
- AFJK N/A
- ASMB $28,326,000.00
- Revenue This Year
- AFJK N/A
- ASMB $267.67
- Revenue Next Year
- AFJK N/A
- ASMB $46.15
- P/E Ratio
- AFJK $40.08
- ASMB N/A
- Revenue Growth
- AFJK N/A
- ASMB N/A
- 52 Week Low
- AFJK $10.15
- ASMB $7.68
- 52 Week High
- AFJK $10.65
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- AFJK N/A
- ASMB 49.37
- Support Level
- AFJK N/A
- ASMB $15.92
- Resistance Level
- AFJK N/A
- ASMB $17.00
- Average True Range (ATR)
- AFJK 0.00
- ASMB 0.94
- MACD
- AFJK 0.00
- ASMB -0.07
- Stochastic Oscillator
- AFJK 0.00
- ASMB 36.15
About AFJK AIMEI HEALTH TECHNOLOGY CO LTD
Aimei Health Technology Co Ltd is a blank check company.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.